

February 13, 2026

## Consolidated Financial Results for the Fiscal Year Ended December 31, 2025 (Under Japanese GAAP)

Company name: Euglena Co., Ltd.  
 Listing: Tokyo Stock Exchange  
 Securities code: 2931  
 URL: <http://www.euglena.jp/>  
 Representative: Mitsuru Izumo, Representative Director, President  
 Inquiries: Tomohiro Wakahara, Director, Co-CEO & CFiO  
 Telephone: +81-3-3453-4907  
 Scheduled date of annual general meeting of shareholders: March 24, 2026  
 Scheduled date to commence dividend payments: March 25, 2026  
 Scheduled date to file annual securities report: March 23, 2026  
 Preparation of supplementary material on financial results: Yes  
 Holding of financial results meeting: Yes (for analysts and institutional investors)

(Yen amounts are rounded down to millions, unless otherwise noted.)

### 1. Consolidated financial results for the fiscal year ended December 31, 2025 (from January 1, 2025 to December 31, 2025)

#### (1) Consolidated operating results

(Percentages indicate year-on-year changes.)

Fiscal year ended	Net sales		Adjusted EBITDA		Operating profit		Ordinary profit		Profit attributable to owners of parent	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
December 31, 2025	50,370	5.8	6,938	60.3	3,123	938.1	2,365	448.0	(805)	-
December 31, 2024	47,618	2.4	4,329	94.8	300	-	431	-	(650)	-

\* From the perspective of shifting to cash flow-oriented management, we disclose Adjusted EBITDA as an indicator of the Company's ability to generate cash flow. For a definition of Adjusted EBITDA and how it is calculated, see 3. Consolidated Financial Forecast for the fiscal year ending December 31, 2026 (January 1, 2026 ~ December 31, 2026)"

Note: Comprehensive income For the fiscal year ended December 31, 2025: ¥462 million [15.5%]  
 For the fiscal year ended December 31, 2024: ¥400 million [-%]

Fiscal year ended	Basic earnings per share	Diluted earnings per share	Return on equity	Ratio of ordinary profit to total assets	Ratio of operating profit to net sales
	Yen	Yen	%	%	%
December 31, 2025	(5.90)	-	(2.6)	3.2	6.2
December 31, 2024	(4.85)	-	(2.5)	0.6	0.6

Reference: Share of profit (loss) of entities accounted for using equity method  
 For the fiscal year ended December 31, 2025: ¥(28) million  
 For the fiscal year ended December 31, 2024: ¥42 million

#### (2) Consolidated financial position

As of	Total assets	Net assets	Equity-to-asset ratio	Net assets per share
	Millions of yen	Millions of yen	%	Yen
December 31, 2025	72,332	28,526	42.7	226.38
December 31, 2024	73,256	32,113	43.3	232.44

Reference: Equity  
 As of December 31, 2025: ¥30,919 million  
 As of December 31, 2024: ¥31,702 million

#### (3) Consolidated cash flows

Fiscal year ended	Cash flows from operating activities	Cash flows from investing activities	Cash flows from financing activities	Cash and cash equivalents at end of period
	Millions of yen	Millions of yen	Millions of yen	Millions of yen
December 31, 2025	5,188	(585)	(2,428)	15,903
December 31, 2024	2,645	(7,990)	(485)	13,731

## 2. Cash dividends

	Annual dividends per share					Total cash dividends (Total)	Payout ratio (Consolidated)	Ratio of dividends to net assets (Consolidated)
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total			
	Yen	Yen	Yen	Yen	Yen	Millions of yen	%	%
Fiscal year ended December 31, 2024	-	0.00	-	0.00	0.00	-	-	-
Fiscal year ended December 31, 2025	-	0.00	-	2.00	2.00	273	-	0.9
Fiscal year ending December 31, 2026 (Forecast)		0.00		0.00	0.00		-	

Note: Dividends for the fiscal year ending December 31, 2025 will be paid from other capital surplus. For details, please refer to "Breakdown of dividends using other capital surplus as a source of dividends" below.

## 3. Forecast of consolidated financial results for the fiscal year ending December 31, 2026 (from January 1, 2026 to December 31, 2026)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Basic earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen	%	Yen
Fiscal year ending December 31, 2026	52,000	3.2	3,200	2.5	2,800	18.4	-	-	-

Reference: Adjusted EBITDA is calculated as EBITDA (operating income + depreciation and amortization of goodwill) + subsidy income + stock-related compensation.

\* **Notes**

- (1) Significant changes in the scope of consolidation during the period: None
- (2) Changes in accounting policies, changes in accounting estimates, and restatement
- (i) Changes in accounting policies due to revisions to accounting standards and other regulations: Yes
- (ii) Changes in accounting policies due to other reasons: None
- (iii) Changes in accounting estimates: None
- (iv) Restatement: None

Note: For details, please refer to Appendix P.13, "3. Please refer to Consolidated Financial Statements and Major Notes (5) Notes on Consolidated Financial Statements (Notes on Changes in Accounting Policy).

- (3) Number of issued shares (common shares)

- (i) Total number of issued shares at the end of the period (including treasury shares)

As of December 31, 2025	136,599,260 shares
As of December 31, 2024	136,411,986 shares

- (ii) Number of treasury shares at the end of the period

As of December 31, 2025	20,822 shares
As of December 31, 2024	20,682 shares

- (iii) Average number of shares outstanding during the period

Fiscal year ended December 31, 2025	136,500,494 shares
Fiscal year ended December 31, 2024	134,315,620 shares

\* Financial results reports are exempt from audit conducted by certified public accountants or an audit firm.

\* Proper use of earnings forecasts, and other special matters

The forward-looking statements, including forecasts of financial results, contained in these materials are based on information currently available to the Company and on certain assumptions deemed to be reasonable. However, the Company makes no guarantee that these forecasts will be achieved. For the conditions on which earnings forecasts are predicated and precautions for using earnings forecasts, see "1. Please refer to "Summary of Business Results (4) Future Outlook".

Breakdown of other dividends using capital surplus as a source of dividends

The breakdown of dividends for the fiscal year ending December 31, 2025 using other capital surplus as a source of dividends is as follows.

Base Date	end of term	sum
Dividends per share	JPY2.00	JPY2.00
Total Dividends	273	273

Note: The percentage of net asset decline is currently being calculated and will be disclosed as soon as it is finalized.

# Consolidated balance sheet

(Millions of yen)

	As of December 31, 2024	As of December 31, 2025
<b>Assets</b>		
Current assets		
Cash and deposits	20,631	21,163
Notes and accounts receivable - trade	4,262	5,043
Merchandise and finished goods	1,845	2,237
Work in process	337	332
Raw materials and supplies	1,478	1,608
Other	2,413	3,241
Allowance for doubtful accounts	(104)	(188)
Total current assets	30,865	33,437
Non-current assets		
Property, plant and equipment		
Buildings and structures	7,553	7,587
Machinery, equipment and vehicles	3,963	3,923
Tools, furniture and fixtures	1,057	1,057
Land	1,912	1,912
Leased assets	43	81
Construction in progress	36	9
Other	-	24
Accumulated depreciation	(8,518)	(8,845)
Total property, plant and equipment	6,048	5,750
Intangible assets		
Goodwill	12,231	11,107
Customer-related intangible assets	19,975	18,310
Other	1,357	1,546
Total intangible assets	33,564	30,964
Investments and other assets		
Investment securities	748	1,523
Guarantee deposits	482	443
Long-term loans receivable	1,054	-
Deferred tax assets	144	106
Other	407	158
Allowance for doubtful accounts	(59)	(52)
Total investments and other assets	2,777	2,179
Total non-current assets	42,390	38,894
Total assets	73,256	72,332

	As of December 31, 2024	As of December 31, 2025
<b>Liabilities</b>		
Current liabilities		
Notes and accounts payable - trade	1,467	1,882
Short-term borrowings	4,144	3,938
Accounts payable - other	3,384	3,518
Contract liabilities	1,408	1,367
Lease liabilities	3	10
Income taxes payable	846	1,635
Provision for bonuses	512	660
Asset retirement obligations	7	21
Other	1,034	943
Total current liabilities	12,811	13,978
Non-current liabilities		
Bonds payable	1,000	1,000
Convertible-bond-type bonds with share acquisition rights	4,800	4,800
Long-term borrowings	15,964	17,916
Lease liabilities	6	16
Provision for retirement benefits for directors (and other officers)	5	6
Retirement benefit liability	420	440
Asset retirement obligations	182	164
Deferred tax liabilities	5,943	5,480
Other	9	2
Total non-current liabilities	28,331	29,827
Total liabilities	41,142	43,805
<b>Net assets</b>		
Shareholders' equity		
Share capital	16,331	16,373
Capital surplus	16,882	16,924
Retained earnings	(2,260)	(3,066)
Treasury shares	(34)	(34)
Total shareholders' equity	30,918	30,196
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	5	14
Deferred gains or losses on hedges	(0)	(0)
Foreign currency translation adjustment	779	710
Remeasurements of defined benefit plans	(0)	(2)
Total accumulated other comprehensive income	784	722
Share acquisition rights	1	39
Non-controlling interests	409	(2,431)
Total net assets	32,113	28,526
Total liabilities and net assets	73,256	72,332

# Consolidated statement of income

(Millions of yen)

	Fiscal year ended December 31, 2024	Fiscal year ended December 31, 2025
Net sales	47,618	50,370
Cost of sales	14,350	15,336
Gross profit	33,267	35,033
Selling, general and administrative expenses	32,966	31,910
Operating profit	300	3,123
Non-operating income		
Interest income	7	76
Subsidy income	102	75
Commission income	1	57
Gain on Liquidation	280	-
Foreign exchange gains	89	-
Share of profit of entities accounted for using equity method	42	-
Surrender value of insurance policies	18	-
Other	194	128
Total non-operating income	736	338
Non-operating expenses		
Interest expenses on bonds	9	14
Interest expenses	469	451
Share of loss of entities accounted for using equity method	-	28
Commission expenses	-	434
Share issuance costs	2	-
Foreign exchange losses	-	55
Other	123	112
Total non-operating expenses	605	1,096
Ordinary profit	431	2,365
Extraordinary income		
Gain on reversal of share acquisition rights	0	0
Gain on sale of non-current assets	92	3
Gain on sale of investment securities	395	-
Total extraordinary income	488	3
Extraordinary losses		
Loss on sale of non-current assets	0	0
Business restructuring expenses	-	264
Impairment losses	1,135	215
Loss on sale of shares of subsidiaries and associates	88	-
Total extraordinary losses	1,225	479
Profit (loss) before income taxes	(305)	1,889
Income taxes - current	813	1,794
Income taxes - deferred	(885)	(431)
Total income taxes	(71)	1,363
Profit (loss)	(233)	526
Profit attributable to non-controlling interests	417	1,331
Loss attributable to owners of parent	(650)	(805)

## Consolidated statement of comprehensive income

(Millions of yen)

	Fiscal year ended December 31, 2024	Fiscal year ended December 31, 2025
Profit (loss)	(233)	526
Other comprehensive income		
Valuation difference on available-for-sale securities	(137)	8
Deferred gains or losses on hedges	(1)	(0)
Foreign currency translation adjustment	776	(69)
Remeasurements of defined benefit plans, net of tax	(4)	(3)
Share of other comprehensive income of entities accounted for using equity method	1	-
Total other comprehensive income	633	(63)
Comprehensive income	400	462
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	(9)	(868)
Comprehensive income attributable to non-controlling interests	409	1,330

## Consolidated statement of changes in equity

Fiscal year ended December 31, 2024

(Millions of yen)

	Shareholders' equity				
	Share capital	Capital surplus	Retained earnings	Treasury shares	Total shareholders' equity
Balance at beginning of period	15,867	15,198	(10,961)	(34)	20,070
Changes during period					
Issuance of new shares	463	463			926
Deficit disposition		(9,396)	9,396		-
Loss attributable to owners of parent			(650)		(650)
Increase by share exchanges		10,615			10,615
Purchase of treasury shares				(0)	(0)
The increase in retained earnings due to the decrease in profits of an equity-method			8		8
Change in scope of consolidation			(52)		(52)
Net changes in items other than shareholders' equity					-
Total changes during period	463	1,683	8,701	(0)	10,848
Balance at end of period	16,331	16,882	(2,260)	(34)	30,918

	Accumulated other comprehensive income					Share acquisition rights	Non-controlling interests	Total net assets
	Valuation difference on available-for-sale securities	Deferred gains or losses on hedges	Foreign currency translation adjustment	Remeasurements of defined benefit plans	Total valuation and translation adjustments			
Balance at beginning of period	138	1	1	1	142	1	-	20,214
Changes during period								
Issuance of new shares								926
Deficit disposition								-
Loss attributable to owners of parent								(650)
Increase by share exchanges								10,615
Purchase of treasury shares								(0)
The increase in retained earnings due to the decrease in profits of an equity-method								8
Change in scope of consolidation								(52)
Net changes in items other than shareholders' equity	(132)	(1)	777	(2)	641	(0)	409	1,050
Total changes during period	(132)	(1)	777	(2)	641	(0)	409	11,898
Balance at end of period	5	(0)	779	(0)	784	1	409	32,113

## Consolidated statement of changes in equity

Fiscal year ended December 31, 2025

(Millions of yen)

	Shareholders' equity				
	Share capital	Capital surplus	Retained earnings	Treasury shares	Total shareholders' equity
Balance at beginning of period	16,331	16,882	(2,260)	(34)	30,918
Changes during period					
Issuance of new shares	42	42			84
Deficit disposition					
Loss attributable to owners of parent			(805)		(805)
Increase by share exchanges					
Purchase of treasury shares				(0)	(0)

The increase in retained earnings due to the decrease in profits of an equity-method					
Change in scope of consolidation					
Net changes in items other than shareholders' equity					
Total changes during period	42	42	(805)	(0)	(721)
Balance at end of period	16,373	16,924	(3,066)	(34)	30,196

	Accumulated other comprehensive income					Share acquisition rights	Non-controlling interests	Total net assets
	Valuation difference on available-for-sale securities	Deferred gains or losses on hedges	Foreign currency translation adjustment	Remeasurements of defined benefit plans	Total valuation and translation adjustments			
Balance at beginning of period	5	(0)	779	(0)	784	1	409	32,113
Changes during period								
Issuance of new shares								84
Deficit disposition								
Loss attributable to owners of parent								(805)
Increase by share exchanges								
Purchase of treasury shares								(0)
The increase in retained earnings due to the decrease in profits of an equity-method								
Change in scope of consolidation								
Net changes in items other than shareholders' equity	8	(0)	(69)	(1)	(62)	38	(2,841)	(2,865)
Total changes during period	8	(0)	(69)	(1)	(62)	38	(2,841)	(3,586)
Balance at end of period	14	(0)	710	(2)	722	39	(2,431)	28,526

## Consolidated statement of cash flows

(Millions of yen)

	Fiscal year ended December 31, 2024	Fiscal year ended December 31, 2025
Cash flows from operating activities		
Profit (loss) before income taxes	(305)	1,889
Depreciation	2,621	2,421
Amortization of goodwill	977	926
Business restructuring expenses	-	264
Impairment losses	1,135	215
Share-based payment expenses	312	398
Loss (gain) on sale of investment securities	(395)	-
Loss (gain) on sale of shares of subsidiaries and associates	88	-
Loss (gain) on sale of property, plant and equipment	(91)	(3)
Surrender value of insurance policies	(18)	-
Increase (decrease) in allowance for doubtful accounts	9	78
Increase (decrease) in provision for retirement benefits and retirement benefits for directors (and other officers)	(3)	17
Increase (decrease) in provision for bonuses	92	144
Interest and dividend income	(7)	(76)
Subsidy income	(102)	(75)
Gain on reversal of share acquisition rights	(0)	(0)
Interest expenses	469	451
Interest expenses on bonds	9	14
Foreign exchange losses (gains)	18	(1)
Share of loss (profit) of entities accounted for using equity method	(42)	28
Decrease (increase) in trade receivables	(193)	(766)
Decrease (increase) in inventories	572	(516)
Increase (decrease) in trade payables	(151)	414
Increase (decrease) in accounts payable - other	(196)	52
Decrease/increase in consumption taxes receivable/payable	273	(58)
Other, net	(1,008)	945
Subtotal	4,065	6,763
Interest and dividends received	7	76
Subsidies received	93	75
Expenses associated with the termination of operation of the demonstration plant	(581)	-
Payments for business restructuring expenses	-	(260)
Interest paid	(478)	(464)
Income taxes paid	(933)	(1,245)
Income taxes refund	472	242
Net cash provided by (used in) operating activities	2,645	5,188

	Fiscal year ended December 31, 2024	Fiscal year ended December 31, 2025
Cash flows from investing activities		
Decrease (increase) in time deposits	(6,726)	1,503
Purchase of property, plant and equipment	(419)	(209)
Proceeds from sale of property, plant and equipment	665	5
Purchase of intangible assets	(313)	(386)
Purchase of investment securities	(118)	(771)
Proceeds from sale and redemption of investment securities	462	-
Proceeds from distributions from investment partnerships	56	-
Decrease (increase) in short-term loans receivable	(13)	(1,748)
Long-term loan advances	(1,043)	-
Proceeds from collection of long-term loans receivable	-	988
Payments of guarantee deposits	(3)	(31)
Proceeds from refund of guarantee deposits	10	70
Proceeds from cancellation of insurance funds	18	-
Payments for asset retirement obligations	(106)	(5)
Payments for sale of shares of subsidiaries resulting in change in scope of consolidation	(505)	-
Proceeds from purchase of shares of subsidiaries resulting in change in scope of consolidation	47	-
Net cash provided by (used in) investing activities	(7,990)	(585)
Cash flows from financing activities		
Increase (decrease) in short-term borrowings	1,289	148
Proceeds from long-term borrowings	1,529	17,560
Repayments of long-term borrowings	(4,294)	(15,959)
Repayments of lease liabilities	(8)	(6)
Proceeds from issuance of bonds	1,000	-
Purchase of treasury shares	(0)	(0)
Dividends paid to non-controlling interests	-	(4,171)
Net cash provided by (used in) financing activities	(485)	(2,428)
Effect of exchange rate change on cash and cash equivalents	779	(2)
Net increase (decrease) in cash and cash equivalents	(5,049)	2,172
Cash and cash equivalents at beginning of period	15,651	13,731
Increase in cash and cash equivalents resulting from share exchanges	3,129	-
Cash and cash equivalents at end of period	13,731	15,903

(Notes on segment information, etc.)

Segment Information

1. Overview of Reporting Segments

The Company's reporting segments are those of the Company's constituent units for which segregated financial information is available and is subject to periodic review by the Board of Directors in order to determine the allocation of management resources and evaluate performance.

The Company is comprised of three reporting segments: Healthcare, Biofuels, and Other Businesses.

The main service and product types for each segment are as follows:

"Healthcare business" ... Planning, manufacturing, sales, and OEM supply of health foods and cosmetics, as well as R&D, production, and sales of microalgae as raw materials for health foods and cosmetics.

"Biofuel Business" ... R&D, manufacturing, and sales of biofuels, and development of microalgae cultivation technology centered on Euglena

"Other Business" ... Manufacture and sale of organic fertilizers, cultivation and sales of shrimp, R&D, production, and sales of microalgae as feed and fertilizer raw materials, genetic analysis services, social business, and research and development in new fields, etc.

2. Method of calculating the amount of sales, profits or losses, assets and other items for each reporting segment

The method of accounting for the reported business segments is generally the same as described in the "Important Matters Underlying the Preparation of Consolidated Financial Statements".

Profit in the reporting segment is a figure based on operating income.

Internal revenues and transfers between segments are based on prevailing market prices.

3. Information on the amount of sales, profits or losses, assets and other items for each reported segment, and information on the breakdown of earnings

The previous fiscal year (January 1, 2024 to December 31, 2024)

(Millions of yen)

	Reportable segments				Adjustment amount (Note 1)	Amount recorded in consolidated financial statements (Note 2)
	Healthcare Business	Biofuel Business	Others Business	Total		
Sales						
Direct sales (Note 3)	33,076	-	-	33,076	-	33,076
Wholesale (Note 4)	3,868	-	-	3,868	-	3,868
OEM, Ingredients Supply, Overseas (Note 5, 6, 7)	5,852	-	-	5,852	-	5,852
Others (Note 8)	1,549	934	2,338	4,821	-	4,821
Revenue from contracts with customers	44,345	934	2,338	47,618	-	47,618
Revenues from external customers	44,345	934	2,338	47,618	-	47,618
Transactions with other segments	1	-	9	10	(10)	-
Total	44,347	934	2,347	47,629	(10)	47,618
Segment profit (loss)	2,953	(410)	(586)	1,956	(1,655)	300
Segment Assets	56,129	9,385	2,751	68,265	4,990	73,256
Other items						
Depreciation and amortization (Note 9)	2,626	(31)	25	2,620	0	2,621
Amortization of goodwill	945	-	32	977	-	977
Increase in property, plant and equipment and intangible assets	658	-	50	709	8	717

Note: 1. The amount of adjustment is as follows.

(1) Adjustments for segment profit or loss (loss) of (1,655) million yen are mainly general and administrative expenses and other company-wide expenses that are not allocated to each reporting segment.

(2) The adjusted amount of segment assets of 4,990 million yen includes cash and deposits of 4,256 million yen that have not been allocated to each reporting segment.

(3) The adjustment for the increase in depreciation, property, plant and equipment and intangible assets is the amount of depreciation and amortization and increase in company-wide assets that have not been allocated to each reporting segment.

2. Segment profit or loss (loss) is adjusted for operating loss in the consolidated statements of income, and segment assets are adjusted for total assets in the consolidated balance sheet.

3. Direct sales are a form of selling the Group's health foods, cosmetics, and other products directly to consumers via the Internet or telephone.

4. Wholesale is a form of wholesaling the Group's health foods and cosmetics directly to various retail stores or through food trading companies, beauty trading companies, etc.

5. OEM is a business model in which product specifications are determined jointly with business partners, products are manufactured by the Group based on orders from business partners, and products are sold to business partners.

6. Ingredients Supply is a business model that provides euglena powder to food manufacturers.

7. Overseas, we are developing our business mainly in East Asia to create the Euglena market outside of Japan.

8. Income from sales and advertising operations mainly from off-the-shelf products, contract analysis services, marketing support services, genetic analysis services, biofuels, fertilizers, etc.

9. Depreciation and amortization of the biofuel business of (31) million yen includes a decrease due to a change in the estimate of asset retirement obligations (current).

The current fiscal year (January 1, 2025 to December 31, 2025)

(Millions of yen)

	Reportable segments				Adjustment amount (Note 1)	Amount recorded in consolidated financial statements (Note 2)
	Healthcare Business	Biofuel Business	Others Business	Total		
Sales						
Direct sales (Note 3)	34,049	-	-	34,049	-	34,049
Wholesale (Note 4)	4,177	-	-	4,177	-	4,177
OEM, Ingredients Supply, Overseas (Note 5, 6, 7)	8,631	-	-	8,631	-	8,631
Others (Note 8)	159	1,092	2,259	3,511	-	3,511
Revenue from contracts with customers	47,018	1,092	2,259	50,370	-	50,370
Revenues from external customers	47,018	1,092	2,259	50,370	-	50,370
Transactions with other segments	2	-	39	41	(41)	-

Total	47,020	1,092	2,298	50,411	(41)	50,370
Segment profit (loss)	5,487	(325)	(533)	4,628	(1,505)	3,123
Segment Assets	52,522	8,357	2,756	63,637	8,695	72,332
Other items						
Depreciation and amortization (Note 9)	2,401	(4)	23	2,421	0	2,421
Amortization of goodwill	894	-	32	926	-	926
Increase in property, plant and equipment and intangible assets	607	7	72	687	5	692

Note: 1. The amount of adjustment is as follows.

- (1) Adjustments for segment profit or loss (loss) of (1,505) million yen are mainly general and administrative expenses and other company-wide expenses that are not allocated to each reporting segment.
- (2) The adjusted amount of 8,695 million yen in segment assets includes 8,490 million yen in cash and deposits that have not been allocated to each reporting segment.
- (3) The adjustment for the increase in depreciation, property, plant and equipment and intangible assets is the amount of depreciation and amortization and increase in company-wide assets that have not been allocated to each reporting segment.
2. Segment profit or loss (loss) is adjusted for operating loss in the consolidated statements of income, and segment assets are adjusted for total assets in the consolidated balance sheet.
3. Direct sales are a form of selling the Group's health foods, cosmetics, and other products directly to consumers via the Internet or telephone.
4. Wholesale is a form of wholesaling the Group's health foods and cosmetics directly to various retail stores or through food trading companies, beauty trading companies, etc.
5. OEM is a business model in which product specifications are determined jointly with business partners, and the Group manufactures products such as functional foods and cosmetics based on orders from business partners, and sells them to business partners.
6. Ingredients Supply is a business model that provides euglena powder to food manufacturers.
7. Overseas is a business model that provides euglena and chlorella powders, products, etc. outside of Japan.
8. Others are revenues from the sale of ready-made products in the healthcare business and income from the biofuels business and other businesses.
9. Depreciation and amortization of the biofuel business of (4) million yen includes a decrease due to a change in the estimate of asset retirement obligations (current).

#### Related Information

The previous fiscal year (January 1, 2024 to December 31, 2024)

##### 1. Product and Service Information

Since the same information is disclosed in the segment information, it is omitted.

##### 2. Regional Information

###### (1) Net sales

Since sales to external customers in Japan exceed 90% of sales in the consolidated statements of income, the description is omitted.

###### (2) Property, plant and equipment

Since Japan's share of total property, plant and equipment exceeds 90%, the description is omitted.

##### 3. Information per main customer

Since there are no counterparties that account for more than 10% of sales in the consolidated statements of income out of sales to external customers, the description is omitted.

The current fiscal year (January 1, 2025 to December 31, 2025)

##### 1. Product and Service Information

Since the same information is disclosed in the segment information, it is omitted.

##### 2. Regional Information

###### (1) Net sales

Since sales to external customers in Japan exceed 90% of sales in the consolidated statements of income, the description is omitted.

###### (2) Property, plant and equipment

Since Japan's share of total property, plant and equipment exceeds 90%, the description is omitted.

##### 3. Information per main customer

Since there are no counterparties that account for more than 10% of sales in the consolidated statements of income out of sales to external customers, the description is omitted.

#### Information on impairment losses on fixed assets by reporting segment

The previous fiscal year (January 1, 2024 to December 31, 2024)

(Millions of yen)

	Healthcare Business	Biofuel Business	Others Business	Total	Reconciling items	Total
Impairment losses	1,095	-	32	1,127	8	1,135

The current fiscal year (January 1, 2025 to December 31, 2025)

(Millions of yen)

	Healthcare Business	Biofuel Business	Others Business	Total	Reconciling items	Total
Impairment losses	197	-	13	211	4	215

#### Information on amortization and unamortized balances of goodwill by reporting segment

The previous fiscal year (January 1, 2024 to December 31, 2024)

(Millions of yen)

	Healthcare Business	Biofuel Business	Others Business	Total	Reconciling items	Total
Depreciation for the period	945	-	32	977	-	977
Balance at the end of the current fiscal year	11,844	-	387	12,231	-	12,231

The current fiscal year (January 1, 2025 to December 31, 2025)

(Millions of yen)

	Healthcare Business	Biofuel Business	Others Business	Total	Reconciling items	Total
Depreciation for the period	894	-	32	926	-	926
Balance at the end of the current fiscal year	10,751	-	355	11,107	-	11,107

#### Information on Negative Goodwill Accrual Gains by Reporting Segment

The previous fiscal year (January 1, 2024 to December 31, 2024)

Not applicable.

The current fiscal year (January 1, 2025 to December 31, 2025)

Not applicable.